Brief: I-Mab Announces Approval From China CDE To Initiate Phase 3 Registrational Study

NovaBridge Biosciences

13/09/2022 15:35

Sept 13 (Reuters) - I-Mab  IMAB.O :
    * I-MAB ANNOUNCES APPROVAL FROM CHINA CDE TO INITIATE PHASE
3
REGISTRATIONAL STUDY OF LEMZOPARLIMAB IN COMBINATION WITH
AZACITIDINE IN HIGHER-RISK MYELODYSPLASTIC SYNDROME
    * I-MAB - ON TRACK TO INITIATE STUDY AS PLANNED

Source text for Eikon:  ID:nPn506jZga 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))